Glenview Capital Management

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Detect they build tools that empower people to understand their health.

Limber Health facilitates the delivery of hybrid musculoskeletal (MSK) care, combining in-person and digital services. Developed by physical therapists and physicians, their platform offers tools for Remote Therapeutic Monitoring, Home Exercise Programs, Outcomes Collection, MIPS Reporting, and supports value-based care.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Identifeye is creating prediction models that combine multiple retinal imaging modalities with expert annotations to create comprehensive and non-invasive health assessments. Identifeye Health is a part of the 4Catalyzer accelerator, which is dedicated to improving patient care globally. It has offices in Guilford, Connecticut, New York City, and Palo Alto, California.

Butterfly Network is a medical technology company developing handheld ultrasound systems that aim to democratize imaging and expand access to care. Its flagship device, a single-probe handheld system powered by Ultrasound-on-Chip semiconductor technology, enables whole-body diagnostic imaging with cloud-connected software and a mobile application, allowing clinicians to acquire, store, and analyze ultrasound data in real time. The platform supports workflow integration for hospitals and outpatient settings, and can image vascular, cardiac, abdominal, urological, fetal, gynecological, and musculoskeletal regions. The company envisions improving early detection and remote management of health conditions by enabling pocket-sized imaging capability and scalable ultrasound programs across healthcare facilities. Butterfly Network was founded with a mission to advance global health equity by increasing ultrasound access worldwide. The technology combines a compact hardware device with software to streamline acquisition, interpretation, and sharing of ultrasound information in clinical workflows.

SunEdison is a global leader in renewable energy solutions, specializing in the development, financing, installation, ownership, and operation of solar power plants. They serve residential, commercial, government, and utility customers worldwide, providing tailored solar energy systems and flexible financing options.

Calypso Medical Technologies is a Seattle-based medical device company that specializes in real-time localization technology for tumor tracking. Its proprietary system employs miniaturized implanted devices, known as Beacon electromagnetic transponders, to continuously and accurately monitor the location of tumors. This innovative approach aims to enhance the precision and management of radiation therapy delivery, particularly for body-wide cancers commonly treated with this method. The company's products have received FDA 510(k) clearance for use in the prostate and post-operative prostatic bed. Calypso Medical has established strategic partnerships with major industry players, including Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.